HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Singh, A. Articles by Ketring, A. R. Search for Related Content PubMed PubMed Citation Articles by Singh, A. Articles by Ketring, A. R.

Human Pharmacokinetics of Samarium-153 EDTMP in Metastatic Cancer

Departments of Radiology and Medicine, University of Missouri Hospital and Clinics, and Nuclear Medicine and Research Services, Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri

Correspondence: For reprints contact: Richard A. Holmes, MD, Section of Nuclear Medicine, 2N-19, One Hospital Dr., University of Missouri Hospital and Clinics, Columbia, MO 65212.

ABSTRACT

Samarium-153 ethylenediaminetetramethylene phosphonic acid ([¹⁵³Sm]EDTMP) has been proposed to palliate pain resulting from osteoblastic metastatic bone cancer. Encouraging results in dogs with primary malignant bone cancer provided the catalysis for human biodistribution studies in five patients with metastatic skeletal carcinoma. The objective was to assess the preferential localization of [¹⁵³Sm]EDTMP in bony lesions and compare it to the ^99mTc-labeled phosphonates. Blood clearance of [¹⁵³Sm]EDTMP was rapid with minimal accumulation in nonosseous tissues. Both radiopharmaceuticals showed identical lesion uptake in 23 paired lesions (p > 0.05). This indicates that the two radiopharmaceuticals concentrate in metastatic skeletal lesions by the same mechanism and since [¹⁵³Sm]EDTMP emits beta radiation it maybe therapeutically useful in ameliorating metastatic bony cancer pain.

This article has been cited by other articles:

				P. M. Anderson, G. A. Wiseman, L. Erlandson, V. Rodriguez, B. Trotz, S. A. Dubansky, and K. Albritton Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma Clin. Cancer Res., October 1, 2005; 11(19): 6895 - 6900. [Abstract] [Full Text] [PDF]

				V. J. Lewington Bone-Seeking Radionuclides For Therapy J. Nucl. Med., January 1, 2005; 46(1_suppl): 38S - 47S. [Abstract] [Full Text] [PDF]

				N. Pandit-Taskar, M. Batraki, and C. R. Divgi Radiopharmaceutical Therapy for Palliation of Bone Pain from Osseous Metastases J. Nucl. Med., August 1, 2004; 45(8): 1358 - 1365. [Abstract] [Full Text] [PDF]

				P. M. Anderson, G. A. Wiseman, A. Dispenzieri, C. A.S. Arndt, L. C. Hartmann, W. A. Smithson, B. P. Mullan, and O. S. Bruland High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone Metastases J. Clin. Oncol., January 1, 2002; 20(1): 189 - 196. [Abstract] [Full Text] [PDF]

				A. N. Serafini Therapy of Metastatic Bone Pain J. Nucl. Med., June 1, 2001; 42(6): 895 - 906. [Abstract] [Full Text] [PDF]

				V. Rodriguez and D. Betcher 153Sm-EDTMP Journal of Pediatric Oncology Nursing, January 1, 1998; 15(2): 95 - 97. [PDF]

				M. Abrams and B. Murrer Metal compounds in therapy and diagnosis Science, August 6, 1993; 261(5122): 725 - 730. [Abstract] [PDF]